These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

223 related items for PubMed ID: 11196534

  • 1. Stromelysin-1 (MMP-3) in synovial fluid of patients with rheumatoid arthritis has potential to cleave membrane bound Fas ligand.
    Matsuno H, Yudoh K, Watanabe Y, Nakazawa F, Aono H, Kimura T.
    J Rheumatol; 2001 Jan; 28(1):22-8. PubMed ID: 11196534
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Matrix metalloproteinases MMP-3 and MMP-1 levels in sera and synovial fluids in patients with rheumatoid arthritis and osteoarthritis.
    Mahmoud RK, El-Ansary AK, El-Eishi HH, Kamal HM, El-Saeed NH.
    Ital J Biochem; 2005 Jan; 54(3-4):248-57. PubMed ID: 16688934
    [Abstract] [Full Text] [Related]

  • 4. Matrix metalloproteinase 9, apoptosis, and vascular morphology in early arthritis.
    Fraser A, Fearon U, Reece R, Emery P, Veale DJ.
    Arthritis Rheum; 2001 Sep; 44(9):2024-8. PubMed ID: 11592363
    [Abstract] [Full Text] [Related]

  • 5. Determination of stromelysin-1, 72 and 92 kDa type IV collagenase, tissue inhibitor of metalloproteinase-1 (TIMP-1), and TIMP-2 in synovial fluid and serum from patients with rheumatoid arthritis.
    Ishiguro N, Ito T, Obata K, Fujimoto N, Iwata H.
    J Rheumatol; 1996 Sep; 23(9):1599-604. PubMed ID: 8877931
    [Abstract] [Full Text] [Related]

  • 6. [Levels of matrix metalloproteinase-3 and urokinase-type plasminogen activator in knee synovial fluids from patients with rheumatoid arthritis and osteoarthritis].
    Gotoh H, Yamada H, Yoshihara Y, Kikuchi T, Obata K, Shinmei M.
    Ryumachi; 1997 Feb; 37(1):3-8. PubMed ID: 9128417
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Soluble Fas ligand inhibits angiogenesis in rheumatoid arthritis.
    Kim WU, Kwok SK, Hong KH, Yoo SA, Kong JS, Choe J, Cho CS.
    Arthritis Res Ther; 2007 Feb; 9(2):R42. PubMed ID: 17459170
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. The evaluation of soluble Fas and soluble Fas ligand levels of bronchoalveolar lavage fluid in lung cancer patients.
    Erdoğan B, Uzaslan E, Budak F, Karadağ M, Ediger D, Oral B, Göral G, Ege E, Gözü O.
    Tuberk Toraks; 2005 Feb; 53(2):127-31. PubMed ID: 16100648
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Correlations between matrix metalloproteinase-9 and adenosine deaminase isozymes in synovial fluid from patients with rheumatoid arthritis.
    Iwaki-Egawa S, WatanabeY, Matsuno H.
    J Rheumatol; 2001 Mar; 28(3):485-9. PubMed ID: 11296946
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Serum and synovial fluid concentrations of matrix metalloproteinases 3 and its tissue inhibitor 1 in juvenile idiopathic arthritides.
    Gattorno M, Vignola S, Falcini F, Sabatini F, Buoncompagni A, Simonini G, Picco P, Pistoia V.
    J Rheumatol; 2002 Apr; 29(4):826-31. PubMed ID: 11950028
    [Abstract] [Full Text] [Related]

  • 18. Enhanced local production of osteopontin in rheumatoid joints.
    Ohshima S, Yamaguchi N, Nishioka K, Mima T, Ishii T, Umeshita-Sasai M, Kobayashi H, Shimizu M, Katada Y, Wakitani S, Murata N, Nomura S, Matsuno H, Katayama R, Kon S, Inobe M, Uede T, Kawase I, Saeki Y.
    J Rheumatol; 2002 Oct; 29(10):2061-7. PubMed ID: 12375312
    [Abstract] [Full Text] [Related]

  • 19. The TNF superfamily member LIGHT contributes to survival and activation of synovial fibroblasts in rheumatoid arthritis.
    Pierer M, Brentano F, Rethage J, Wagner U, Hantzschel H, Gay RE, Gay S, Kyburz D.
    Rheumatology (Oxford); 2007 Jul; 46(7):1063-70. PubMed ID: 17426140
    [Abstract] [Full Text] [Related]

  • 20. Extracellular calreticulin is present in the joints of patients with rheumatoid arthritis and inhibits FasL (CD95L)-mediated apoptosis of T cells.
    Tarr JM, Winyard PG, Ryan B, Harries LW, Haigh R, Viner N, Eggleton P.
    Arthritis Rheum; 2010 Oct; 62(10):2919-29. PubMed ID: 20533543
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 12.